©2025 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2023

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

Show Description +

Joseph M. Coney, MD, FASRS, explains the study design and rationale for Elevatum, a phase 4 trial of faricimab (Vabysmo, Genentech/Roche) in underrepresented patients with DME.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Elevatum

•

Clinical Trials

•

faricimab

•

Vabysmo

•

Genentech

•

Roche

•

underrepresented

•

Diabetic macular edema, DME

Up Next

A Closer Look at 8 mg Aflibercept
A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Biosimilars in the Real World
Biosimilars in the Real World

Carl C. Awh, MD, FASRS

An Update on Suprachoroidal RGX-314
An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Treating GA With ANX007
Treating GA With ANX007

Jeffrey S. Heier, MD

Introducing a TWO-ROP Algorithm
Introducing a TWO-ROP Algorithm

Nimesh A. Patel, MD

When Infectious Retinitis Leads to an RD
When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH
ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy
Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV
Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Methotrexate Shows Promise for Preventing PVR
Methotrexate Shows Promise for Preventing PVR

Christina J. Flaxel, MD

Codes for Concurrent GA and Wet AMD
Codes for Concurrent GA and Wet AMD

Jong G. Park, MD

High-Dose Aflibercept: 48-Week Data
High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Defining Anti-VEGF Response in CI-DME
Defining Anti-VEGF Response in CI-DME

Sharon D. Solomon, MD

link-arrow   Back to All Videos

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

Joseph M. Coney, MD, FASRS, explains the study design and rationale for Elevatum, a phase 4 trial of faricimab (Vabysmo, Genentech/Roche) in underrepresented patients with DME.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Elevatum

•

Clinical Trials

•

faricimab

•

Vabysmo

•

Genentech

•

Roche

•

underrepresented

•

Diabetic macular edema, DME

Please log in to leave a comment.

More From ASRS: 2023 Coverage

When Infectious Retinitis Leads to an RD
When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH
ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy
Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV
Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2023.

close-x